| Autor: |
Abdallah Hadj Tahar, Laurent Grégoire, Aurélie Darré, Nancy Bélanger, Leonard Meltzer, Paul J Bédard |
| Jazyk: |
angličtina |
| Rok vydání: |
2004 |
| Předmět: |
|
| Zdroj: |
Neurobiology of Disease, Vol 15, Iss 2, Pp 171-176 (2004) |
| Druh dokumentu: |
article |
| ISSN: |
1095-953X |
| DOI: |
10.1016/j.nbd.2003.10.007 |
| Popis: |
Alterations of striatal glutamate receptors are believed to be responsible, at least in part, for the pathogenesis of l-dopa-induced dyskinesias (LID). To evaluate whether co-administration of CI-1041, a novel NMDA receptor antagonist selective for the NR1A/NR2B subtype, with l-dopa might prevent the appearance of this side effect, eight de novo parkinsonian monkeys were treated chronically orally with either l-dopa alone or l-dopa plus CI-1041 (n= 4 for each group). After 4 weeks of treatment with l-dopa alone, all four animals developed moderate dyskinesias either choreic or dystonic in nature. CI-1041 co-treatment completely prevented the induction of dyskinesias in three animals and only one monkey developed mild dyskinesias at the end of the fourth week of treatment in the l-dopa + CI-1041 group. The magnitude and duration of the antiparkinsonian action of l-dopa was similar in both groups. These results suggest that selective NMDA receptor antagonism may be interesting for managing LID in Parkinson's disease patients. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full Text from ScienceDirect